DR REDDYS LABORATORIES LTD
RDY evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for RDY—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · RDY
Dr. Reddy's Laboratories Ltd is an integrated global pharmaceutical company focused on affordable and innovative medicines, with operations spanning generics, biosimilars, active pharmaceutical ingredients, and consumer healthcare.
Key risk: Regulatory approval delays
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Mar 31, 2025.
Tracking 65 pipeline candidates · 135 FDA decisions for DR REDDYS LABORATORIES LTD.
Dr. Reddy's Laboratories Ltd is an integrated global pharmaceutical company focused on affordable and innovative medicines, with operations spanning generics, biosimilars, active pharmaceutical ingredients, and consumer healthcare.
- As of March 31, 2026, Dr. Reddy's had 77 generic filings pending U.S. FDA approval, including 75 ANDAs and 2 NDAs under Section 505(b)(2) [sec · filed 2026-05-29].
- The company has three ongoing Biologics License Applications (BLAs) pending with the U.S. FDA for biosimilar candidates: Abatacept (IV), Rituximab, and Denosumab [sec · filed 2026-05-29].
- Cash and equivalents stood at $172.0M as of March 31, 2025, with shareholders' equity of $3,366.0M and total debt of $298.0M [sec].
- Dr. Reddy's has expanded its biosimilars pipeline through partnerships, including a 2024 deal with Alvotech for denosumab and a 2025 deal with Shanghai Henlius Biotech for daratumumab biosimilar HLX15 [sec · filed 2026-05-29].
- As of June 30, 2026, the company had 79 filings pending U.S. FDA approval, including 76 ANDAs and 3 NDAs, with 45 Paragraph IV filings and 24 first-to-file status [sec · filed 2026-07-22].
What works
- Strong generic pipeline with 77 filings pending as of March 31, 2026, including 43 Paragraph IV applications and 22 with first-to-file status, positioning for potential market exclusivity [sec · filed 2026-05-29].
- Biosimilar portfolio advancing with three BLAs under FDA review, including Rituximab where all clinical trials are completed and the BLA is under active review [sec · filed 2026-05-29].
- Diversified business model across Global Generics, PSAI, and Consumer Healthcare segments, providing multiple revenue streams and risk mitigation [sec · filed 2026-05-29].
What to weigh
- The company faces risks from regulatory approval timelines, including staffing and policy changes at the U.S. FDA, which could delay product launches [sec · filed 2026-05-29].
- Exposure to foreign currency fluctuations and global economic volatility may adversely affect financial results and cash flows [sec · filed 2026-05-29].
- Significant environmental compliance obligations and potential penalties for non-compliance could impact operations and costs [sec · filed 2026-05-29].
From the filings
Quoted directly from source documents.
Dr. Reddy's has a large pending ANDA pipeline with many Paragraph IV and first-to-file applications.
“As of March 31, 2026, 77 generic filings were pending approval from the U.S. FDA. These are comprised of 75 ANDAs and 2 New Drug Applications ("NDAs") filed under Section 505(b)(2) of the U.S. Federal Food, Drug, and Cosmetic Act. Of the 75 ANDAs, 43 are Paragraph IV applications, and we believe that 22 of these have the 'First to File' status.”
SEC filings · March 31, 2026
Three biosimilar BLAs are pending FDA approval, with Rituximab under active review.
“As of March 31, 2026, we have three ongoing Biologics License Applications ("BLA") pending approval with the U.S. FDA for our proposed biosimilar-Abatacept (for intravenous presentation), Rituximab and Denosumab. For Rituximab, all clinical trials have been successfully completed, and our BLA is under active review with the U.S. FDA.”
SEC filings · March 31, 2026
Risks & what to watch (3)›
Key risks
- Regulatory approval delays — Staffing and policy changes at the U.S. FDA could delay product approvals and launches [sec · filed 2026-05-29].
- Foreign currency exposure — Fluctuations in key foreign currencies may adversely affect financial results and cash flows [sec · filed 2026-05-29].
- Environmental compliance costs — Significant environmental regulations could lead to penalties or facility closures if not met [sec · filed 2026-05-29].
What to watch
- FDA decisions on three pending BLAs for biosimilar candidates (Abatacept, Rituximab, Denosumab) [sec · filed 2026-05-29].
- Approval and launch of pending ANDAs, especially the 22 first-to-file Paragraph IV applications [sec · filed 2026-05-29].
- Progress of biosimilar partnerships with Alvotech and Shanghai Henlius for commercialization in the U.S. and Europe [sec · filed 2026-05-29].
- Completion of major capital expansion projects expected by fiscal year ending March 31, 2027 [sec · filed 2026-05-29].
Sources: SEC filings · Generated August 29, 2026 · How we verify sources →
Run DR REDDYS LABORATORIES LTD through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available DR REDDYS LABORATORIES LTD facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.46
Lead: Approved
65 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
244
Total value held
$1.24B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 11,587,127 | $160.5M |
| royal bank of canada | 9,984,082 | $138.3M |
| morgan stanley | 9,371,594 | $129.8M |
| renaissance technologies llc | 7,859,728 | $108.9M |
| vanguard capital management llc | 6,201,822 | $85.9M |
| dimensional fund advisors lp | 5,323,248 | $73.7M |
| state street corp | 4,026,207 | $55.8M |
| bnp paribas financial markets | 3,183,971 | $44.1M |
| franklin resources inc | 2,856,094 | $39.6M |
| marshall wace, llp | 2,664,306 | $36.9M |
Showing top 10 of 244 institutional holders of DR REDDYS LABORATORIES LTD. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 3.7%
- Days to cover
- 6.1
- Shares short
- 15,719,527
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
RDY short interestFrequently asked questions
What is the AI investment thesis for DR REDDYS LABORATORIES LTD?
Dr. Reddy's Laboratories Ltd is an integrated global pharmaceutical company focused on affordable and innovative medicines, with operations spanning generics, biosimilars, active pharmaceutical ingredients, and consumer healthcare.
What is DR REDDYS LABORATORIES LTD's lead drug candidate?
DR REDDYS LABORATORIES LTD's most advanced tracked candidate is abiraterone (Approved).
Who is the CEO of DR REDDYS LABORATORIES LTD?
Mr. Erez Israeli M.B.A. is the chief executive officer of DR REDDYS LABORATORIES LTD (RDY).
Where is DR REDDYS LABORATORIES LTD headquartered?
DR REDDYS LABORATORIES LTD (RDY) is headquartered in Hyderabad, India.
What therapeutic areas does DR REDDYS LABORATORIES LTD focus on?
DR REDDYS LABORATORIES LTD develops therapies across Oncology, Respiratory, Pain.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.